Real-world Dosing Patterns of Rivaroxaban in the United States (RIVA-D)

Trial Profile

Real-world Dosing Patterns of Rivaroxaban in the United States (RIVA-D)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms RIVA-D
  • Sponsors Bayer
  • Most Recent Events

    • 10 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top